choline 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
3097 62-49-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • choline chloride
  • choline
  • vitamin J
  • bilineurine
  • choline ion
  • choline bitartrate
A basic constituent of lecithin that is found in many plants and animal organs. It is important as a precursor of acetylcholine, as a methyl donor in various metabolic processes, and in lipid metabolism.
  • Molecular weight: 104.17
  • Formula: C5H14NO
  • CLOGP: -4.36
  • LIPINSKI: 0
  • HAC: 2
  • HDO: 1
  • TPSA: 20.23
  • ALOGS: -1.59
  • ROTB: 2
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 -4.397 High 1
caco2-efflux Caco-2 efflux ratio (BA/AB) 0.042 High 1
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 0.493 10^-6 cm/s High 1
dh-clint Dog hepatocyte intrinsic clearance 3.483 uL/min/10^6 cells High 1
dppb Dog plasma protein binding (% unbound) 84.300 % High 1
fcs-ppb Fetal calf serum protein binding (% unbound) 33.640 % High 1
herg hERG pIC50 3.917 pIC50 High 1
hh-clint Human hepatocyte intrinsic clearance 1.524 uL/min/10^6 cells High 1
hlm-clint Human liver microsomal intrinsic clearance 2.472 uL/min/mg protein High 1
hppb Human plasma protein binding (% unbound) 84.510 % High 1
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 0.041 High 1
mh-clint Mouse hepatocyte intrinsic clearance 2.704 High 1
mppb Mouse plasma protein binding (% unbound) 94.350 High 1
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 0.128 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 83.620 % High 1
rh-clint Rat hepatocyte intrinsic clearance 1.799 uL/min/10^6 cells High 1
rh-fuinc Rat hepatocyte fraction unbound in incubation 92.870 % High 1
rppb Rat plasma protein binding (% unbound) 94.620 % High 1
solubility-dd Solubility at pH 7.4 in DMSO 920.450 uM High 1

Approvals:

DateAgencyCompanyOrphan
None FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Synovitis 133.64 11.73 3 40694 329749 90258001
Diarrhoea 114.35 11.73 766 39931 938424 89649326
Product use in unapproved indication 114.09 11.73 10 40687 336226 90251524
Product dose omission issue 112.98 11.73 337 40360 291350 90296400
Systemic lupus erythematosus 112.04 11.73 15 40682 361881 90225869
Glossodynia 105.39 11.73 11 40686 321768 90265982
Pericarditis 103.83 11.73 4 40693 270147 90317603
Treatment failure 97.97 11.73 11 40686 303917 90283833
Maternal exposure during pregnancy 92.14 11.73 24 40673 360039 90227711
Infusion related reaction 92.10 11.73 36 40661 416744 90171006
Wound 90.40 11.73 14 40683 302966 90284784
Fall 90.02 11.73 441 40256 481369 90106381
Off label use 88.03 11.73 232 40465 1102020 89485730
Drug intolerance 85.99 11.73 47 40650 447544 90140206
Helicobacter infection 85.04 11.73 4 40693 226846 90360904
Product use issue 84.39 11.73 22 40675 329897 90257853
Unevaluable event 79.34 11.73 110 40587 54738 90533012
Folliculitis 75.33 11.73 4 40693 204349 90383401
Device expulsion 74.70 11.73 92 40605 40794 90546956
Fatigue 70.60 11.73 809 39888 1153214 89434536
Hepatic enzyme increased 63.47 11.73 42 40655 360694 90227056
Lower respiratory tract infection 61.67 11.73 18 40679 250641 90337109
Arthropathy 60.03 11.73 46 40651 366196 90221554
Full blood count decreased 59.46 11.73 70 40627 29619 90558131
Type 2 diabetes mellitus 59.24 11.73 10 40687 203234 90384516
Feeling abnormal 58.86 11.73 187 40510 167048 90420702
Deep vein thrombosis 58.51 11.73 128 40569 91492 90496258
Intentional product use issue 58.30 11.73 13 40684 216879 90370871
Muscle spasms 56.91 11.73 244 40453 251639 90336111
Nausea 56.84 11.73 753 39944 1109563 89478187
Liver injury 55.37 11.73 6 40691 170561 90417189
Device dislocation 54.56 11.73 69 40628 31413 90556337
Therapeutic product effect decreased 52.03 11.73 30 40667 277541 90310209
Neuropathy peripheral 51.74 11.73 157 40540 136813 90450937
Therapy cessation 51.20 11.73 72 40625 36289 90551461
Drug hypersensitivity 50.92 11.73 81 40616 463528 90124222
Irritable bowel syndrome 50.84 11.73 15 40682 207433 90380317
Drug ineffective 49.54 11.73 392 40305 1383906 89203844
General physical health deterioration 49.34 11.73 52 40645 355063 90232687
C-reactive protein increased 48.49 11.73 11 40686 181378 90406372
Dizziness 48.22 11.73 439 40258 588845 89998905
Haemoglobin decreased 48.04 11.73 171 40526 161785 90425965
Therapeutic product effect incomplete 47.55 11.73 14 40683 193882 90393868
Fibromyalgia 42.03 11.73 20 40677 206249 90381501
Constipation 41.54 11.73 241 40456 280154 90307596
Plasma cell myeloma 40.82 11.73 69 40628 40759 90546991
Blister 40.53 11.73 33 40664 254965 90332785
Dehydration 39.84 11.73 183 40514 194264 90393486
Ill-defined disorder 39.12 11.73 17 40680 184874 90402876
Back pain 39.08 11.73 260 40437 316915 90270835
Impaired healing 38.88 11.73 29 40668 234170 90353580
Asthenia 37.89 11.73 386 40311 533365 90054385
Flatulence 37.55 11.73 67 40630 41300 90546450
Discomfort 36.08 11.73 42 40655 274293 90313457
Joint swelling 35.54 11.73 112 40585 503188 90084562
Toxicity to various agents 34.79 11.73 47 40650 287799 90299951
Psoriasis 34.79 11.73 145 40552 147609 90440141
Joint range of motion decreased 34.73 11.73 9 40688 135634 90452116
Pulmonary embolism 34.49 11.73 133 40564 130687 90457063
Urinary tract infection 34.36 11.73 245 40452 305387 90282363
Pneumonia 33.84 11.73 436 40261 637623 89950127
Headache 33.74 11.73 559 40138 862187 89725563
Prescribed overdose 32.81 11.73 3 40694 97622 90490128
Bursitis 31.38 11.73 10 40687 131644 90456106
Intentional overdose 31.23 11.73 3 40694 93831 90493919
Hot flush 30.21 11.73 76 40621 59412 90528338
Injection site pain 29.51 11.73 155 40542 173544 90414206
Injection site erythema 28.34 11.73 103 40594 98399 90489351
Exposure during pregnancy 27.73 11.73 40 40657 238370 90349380
Wheezing 27.64 11.73 40 40657 238040 90349710
Influenza like illness 27.30 11.73 89 40608 80522 90507228
Injection site haemorrhage 27.17 11.73 47 40650 28271 90559479
Pelvic pain 27.15 11.73 34 40663 15323 90572427
Obesity 27.01 11.73 7 40690 105500 90482250
Tremor 26.93 11.73 138 40559 153035 90434715
Asthma 26.84 11.73 42 40655 242118 90345632
Rheumatoid arthritis 26.78 11.73 79 40618 362535 90225215
Grip strength decreased 26.00 11.73 5 40692 92571 90495179
Hip fracture 25.56 11.73 50 40647 33027 90554723
Wound infection 25.50 11.73 8 40689 106394 90481356
Laboratory test abnormal 25.05 11.73 57 40640 41797 90545953
Peripheral venous disease 24.73 11.73 4 40693 83917 90503833
Atrial fibrillation 24.63 11.73 122 40575 133489 90454261
Hypersensitivity 24.43 11.73 113 40584 454564 90133186
Sleep disorder 24.26 11.73 32 40665 197998 90389752
Blood potassium decreased 24.26 11.73 61 40636 47666 90540084
Dyspnoea 24.21 11.73 541 40156 880414 89707336
Skin discolouration 23.96 11.73 58 40639 44257 90543493
Mobility decreased 23.72 11.73 48 40649 250686 90337064
White blood cell count decreased 23.66 11.73 142 40555 166967 90420783
Blood cholesterol increased 23.12 11.73 36 40661 207976 90379774
COVID-19 23.11 11.73 25 40672 168818 90418932
Nasal congestion 22.97 11.73 86 40611 83328 90504422
Vaginal haemorrhage 22.64 11.73 46 40651 31225 90556525
Hypervolaemia 22.32 11.73 47 40650 32710 90555040
Eye swelling 22.20 11.73 44 40653 29342 90558408
Alopecia 22.13 11.73 131 40566 494940 90092810
Epilepsy 21.93 11.73 5 40692 82201 90505549
Gastrointestinal disorder 21.92 11.73 52 40645 256635 90331115
Balance disorder 21.85 11.73 94 40603 96986 90490764
Cardiac failure congestive 21.79 11.73 95 40602 98599 90489151
Pulmonary arterial hypertension 20.74 11.73 40 40657 26147 90561603
Live birth 20.73 11.73 5 40692 79102 90508648
Thrombosis 20.56 11.73 76 40621 73175 90514575
Vision blurred 20.53 11.73 101 40596 110192 90477558
Pulmonary hypertension 20.22 11.73 53 40644 42470 90545280
Infection 20.03 11.73 89 40608 362005 90225745
Fluid retention 19.60 11.73 85 40612 88006 90499744
Hypoxia 19.40 11.73 74 40623 72325 90515425
Chills 19.23 11.73 113 40584 131868 90455882
Platelet count decreased 19.14 11.73 116 40581 136853 90450897
Dry skin 18.85 11.73 84 40613 87989 90499761
Multiple sclerosis relapse 18.85 11.73 59 40638 52246 90535504
Overdose 18.79 11.73 26 40671 157683 90430067
Dysgeusia 18.67 11.73 59 40638 52501 90535249
Dyspnoea exertional 18.64 11.73 73 40624 72215 90515535
Lung disorder 18.58 11.73 24 40673 149859 90437891
Autoimmune disorder 17.98 11.73 6 40691 76738 90511012
Product complaint 17.92 11.73 26 40671 13474 90574276
Condition aggravated 17.90 11.73 176 40521 595369 89992381
Flushing 17.89 11.73 83 40614 88408 90499342
Adverse event 17.66 11.73 16 40681 117402 90470348
International normalised ratio increased 17.63 11.73 54 40643 47262 90540488
Swelling 17.62 11.73 113 40584 418945 90168805
Inflammation 17.05 11.73 34 40663 178558 90409192
Pulmonary fibrosis 16.96 11.73 14 40683 107489 90480261
Pleural effusion 16.38 11.73 96 40601 111895 90475855
Bone pain 16.31 11.73 63 40634 61920 90525830
Oedema peripheral 16.13 11.73 182 40515 257733 90330017
Stomatitis 16.12 11.73 66 40631 274632 90313118
Myalgia 16.09 11.73 134 40563 174991 90412759
Tooth disorder 16.07 11.73 40 40657 31050 90556700
Hypertension 16.03 11.73 130 40567 457402 90130348
Body height decreased 15.85 11.73 23 40674 11926 90575824
Cellulitis 15.84 11.73 82 40615 91255 90496495
Suicide attempt 15.83 11.73 7 40690 75392 90512358
Injection site mass 15.41 11.73 32 40665 22058 90565692
Gallbladder disorder 15.38 11.73 30 40667 19773 90567977
Red blood cell sedimentation rate increased 15.35 11.73 9 40688 82586 90505164
Administration site swelling 15.01 11.73 9 40688 1490 90586260
Hospice care 14.84 11.73 20 40677 9684 90578066
Red blood cell count decreased 14.64 11.73 50 40647 46301 90541449
Pollakiuria 14.54 11.73 40 40657 32965 90554785
Injection site bruising 14.45 11.73 54 40643 52253 90535497
Hypophagia 14.32 11.73 42 40655 35895 90551855
Swelling face 14.09 11.73 73 40624 81279 90506471
Depression 14.07 11.73 201 40496 300400 90287350
Burning sensation 13.94 11.73 61 40636 63391 90524359
Plasma cell myeloma recurrent 13.91 11.73 13 40684 4215 90583535
Anaemia 13.86 11.73 229 40468 352573 90235177
Intestinal dilatation 13.70 11.73 10 40687 2300 90585450
Abdominal discomfort 13.53 11.73 143 40554 477185 90110565
Drug interaction 13.51 11.73 71 40626 276382 90311368
Heavy menstrual bleeding 13.46 11.73 29 40668 20501 90567249
Cardiac pacemaker insertion 13.45 11.73 13 40684 4394 90583356
Lethargy 13.34 11.73 60 40637 63079 90524671
Epistaxis 13.12 11.73 74 40623 85051 90502699
Multiple allergies 13.07 11.73 24 40673 15122 90572628
Injection site reaction 12.87 11.73 78 40619 92002 90495748
Pain in jaw 12.81 11.73 49 40648 47936 90539814
Restless legs syndrome 12.78 11.73 30 40667 22440 90565310
Drug-induced liver injury 12.78 11.73 13 40684 90305 90497445
Abdominal pain 12.77 11.73 249 40448 395472 90192278
Night sweats 12.73 11.73 24 40673 128742 90459008
Intermenstrual bleeding 12.59 11.73 18 40679 9205 90578545
Illness 12.53 11.73 11 40686 81958 90505792
Liver disorder 12.53 11.73 22 40675 121247 90466503
Bronchitis 12.48 11.73 114 40583 152813 90434937
Pulmonary oedema 12.38 11.73 58 40639 62022 90525728
Haematocrit decreased 12.24 11.73 44 40653 41788 90545962
Complication associated with device 12.21 11.73 27 40670 19422 90568328
Osteoarthritis 12.13 11.73 46 40651 195684 90392066
Ageusia 12.06 11.73 24 40673 16052 90571698
Blepharospasm 11.88 11.73 5 40692 55440 90532310
Cough 11.84 11.73 232 40465 368730 90219020
Anxiety 11.77 11.73 200 40497 309572 90278178

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Off label use 117.99 13.09 110 23650 638225 41959350
Product use in unapproved indication 82.91 13.09 5 23755 184451 42413124
Fatigue 65.18 13.09 440 23320 435201 42162374
Plasma cell myeloma 55.41 13.09 97 23663 47481 42550094
Fall 49.84 13.09 260 23500 234260 42363315
Diarrhoea 43.42 13.09 419 23341 460430 42137145
Full blood count decreased 41.20 13.09 54 23706 20506 42577069
Product dose omission issue 40.57 13.09 182 23578 154183 42443392
Asthenia 40.27 13.09 281 23479 280512 42317063
Laboratory test abnormal 39.46 13.09 56 23704 22922 42574653
Gait spastic 39.17 13.09 18 23742 1391 42596184
Needle fatigue 38.50 13.09 17 23743 1196 42596379
Completed suicide 36.95 13.09 5 23755 96460 42501115
Dizziness 36.64 13.09 251 23509 249003 42348572
Drug interaction 36.36 13.09 58 23702 266941 42330634
White blood cell count decreased 35.11 13.09 138 23622 110258 42487317
Relapsing-remitting multiple sclerosis 35.10 13.09 17 23743 1478 42596097
Multiple sclerosis relapse 34.22 13.09 41 23719 14223 42583352
Drug ineffective 30.64 13.09 216 23544 629981 41967594
Muscle spasticity 29.74 13.09 27 23733 6795 42590780
Toxicity to various agents 29.12 13.09 52 23708 229084 42368491
Memory impairment 28.95 13.09 77 23683 50145 42547430
Adverse drug reaction 28.63 13.09 64 23696 37370 42560205
COVID-19 27.78 13.09 15 23745 115933 42481642
Hypertonic bladder 27.68 13.09 17 23743 2364 42595211
Pneumonia 27.00 13.09 356 23404 421793 42175782
Monoparesis 24.31 13.09 17 23743 2943 42594632
Viral infection 23.81 13.09 44 23716 22439 42575136
Hypoaesthesia 23.24 13.09 90 23670 71373 42526202
Psoriasis 22.63 13.09 69 23691 48535 42549040
Balance disorder 22.52 13.09 68 23692 47577 42549998
General physical health deterioration 22.36 13.09 31 23729 151215 42446360
Intentional product use issue 20.86 13.09 7 23753 71826 42525749
Neuropathy peripheral 20.25 13.09 111 23649 101742 42495833
Sinusitis 20.05 13.09 65 23695 47227 42550348
Muscle spasms 20.04 13.09 98 23662 85946 42511629
Intentional product misuse 19.87 13.09 5 23755 61895 42535680
Central nervous system lesion 19.50 13.09 23 23737 7847 42589728
Rash 18.68 13.09 236 23524 276718 42320857
Influenza 18.37 13.09 76 23684 62099 42535476
Treatment failure 18.36 13.09 6 23754 62618 42534957
Interstitial lung disease 17.58 13.09 11 23749 78451 42519124
Multiple organ dysfunction syndrome 17.45 13.09 17 23743 97018 42500557
Unevaluable event 17.21 13.09 50 23710 34238 42563337
Overdose 17.19 13.09 20 23740 105244 42492331
Cardiac disorder 17.04 13.09 63 23697 48869 42548706
Peripheral swelling 17.03 13.09 97 23663 90173 42507402
Dehydration 16.92 13.09 136 23624 141631 42455944
Haemoglobin decreased 16.87 13.09 129 23631 132342 42465233
Febrile neutropenia 16.48 13.09 51 23709 185652 42411923
Constipation 16.39 13.09 150 23610 162141 42435434
Drug ineffective for unapproved indication 16.30 13.09 3 23757 46160 42551415
Influenza like illness 15.57 13.09 46 23714 31794 42565781
Cytokine release syndrome 15.49 13.09 3 23757 44524 42553051
Small intestinal obstruction 15.15 13.09 31 23729 17030 42580545
Hepatic function abnormal 15.01 13.09 5 23755 51562 42546013
Foetal exposure during pregnancy 14.84 13.09 4 23756 47307 42550268
Micturition urgency 14.81 13.09 25 23735 11873 42585702
Pollakiuria 14.51 13.09 36 23724 22469 42575106
Mental status changes 14.48 13.09 54 23706 42061 42555514
Coma 14.24 13.09 6 23754 53548 42544027
Platelet count decreased 13.94 13.09 128 23632 138453 42459122
Flatulence 13.92 13.09 38 23722 25114 42572461
Insomnia 13.87 13.09 113 23647 118140 42479435
Nocturia 13.20 13.09 24 23736 12088 42585487
Feeling abnormal 13.16 13.09 75 23685 69711 42527864

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Off label use 162.05 11.18 278 50719 1499907 109038395
Product use in unapproved indication 160.54 11.18 12 50985 447365 110090937
Fall 111.37 11.18 561 50436 602921 109935381
Product dose omission issue 108.78 11.18 361 50636 321421 110216881
Treatment failure 100.65 11.18 7 50990 277227 110261075
Completed suicide 88.33 11.18 6 50991 242375 110295927
Diarrhoea 87.77 11.18 855 50142 1138650 109399652
Device expulsion 82.92 11.18 86 50911 30805 110507497
Systemic lupus erythematosus 82.78 11.18 10 50987 254328 110283974
Drug intolerance 81.35 11.18 43 50954 406469 110131833
Dizziness 78.15 11.18 570 50427 697623 109840679
Drug ineffective 73.10 11.18 408 50589 1520132 109018170
Fatigue 72.06 11.18 866 50131 1215092 109323210
Plasma cell myeloma 71.06 11.18 114 50883 62822 110475480
Infusion related reaction 71 11.18 44 50953 381118 110157184
Product use issue 70.07 11.18 28 50969 311667 110226635
Drug abuse 68.96 11.18 3 50994 177408 110360894
Duodenal ulcer perforation 65.93 11.18 4 50993 177696 110360606
Helicobacter infection 64.83 11.18 5 50992 181872 110356430
Glossodynia 64.73 11.18 12 50985 221992 110316310
Intentional product use issue 63.14 11.18 18 50979 247888 110290414
Deep vein thrombosis 62.29 11.18 173 50824 139714 110398588
Asthenia 60.92 11.18 533 50464 688466 109849836
Maternal exposure during pregnancy 60.46 11.18 21 50976 254862 110283440
Pericarditis 59.45 11.18 14 50983 219100 110319202
Dehydration 58.00 11.18 269 50728 279242 110259060
Haemoglobin decreased 57.34 11.18 247 50750 248480 110289822
Toxicity to various agents 57.28 11.18 83 50914 480472 110057830
Folliculitis 56.03 11.18 6 50991 167647 110370655
Lower respiratory tract infection 56.01 11.18 21 50976 243085 110295217
General physical health deterioration 54.16 11.18 70 50927 425225 110113077
Therapy cessation 53.05 11.18 83 50914 44774 110493528
Drug hypersensitivity 52.59 11.18 80 50917 454010 110084292
Therapeutic product effect incomplete 50.45 11.18 20 50977 223785 110314517
Full blood count decreased 48.99 11.18 67 50930 32032 110506270
Hepatic enzyme increased 48.33 11.18 46 50951 320846 110217456
Unevaluable event 48.31 11.18 93 50904 59134 110479168
Feeling abnormal 47.58 11.18 187 50810 180524 110357778
COVID-19 47.43 11.18 27 50970 245033 110293269
Multiple sclerosis relapse 47.40 11.18 84 50913 50156 110488146
Device dislocation 46.63 11.18 65 50932 31639 110506663
Irritable bowel syndrome 45.52 11.18 10 50987 164205 110374097
Nausea 44.92 11.18 809 50188 1234881 109303421
Drug interaction 44.78 11.18 103 50894 500080 110038222
Needle fatigue 44.33 11.18 18 50979 1246 110537056
Gait spastic 44.05 11.18 19 50978 1530 110536772
C-reactive protein increased 43.64 11.18 23 50974 217896 110320406
Intentional overdose 43.62 11.18 5 50992 132496 110405806
Type 2 diabetes mellitus 43.07 11.18 14 50983 177218 110361084
Pneumonia 41.95 11.18 601 50396 876113 109662189
Relapsing-remitting multiple sclerosis 41.69 11.18 20 50977 2062 110536240
Wound 41.01 11.18 29 50968 234408 110303894
Fibromyalgia 40.66 11.18 14 50983 170895 110367407
Arthropathy 39.04 11.18 45 50952 287477 110250825
Liver injury 38.14 11.18 11 50986 150402 110387900
Muscle spasms 37.51 11.18 238 50759 277919 110260383
Intentional product misuse 37.03 11.18 8 50989 132896 110405406
Dyspnoea 36.82 11.18 715 50282 1106157 109432145
Joint swelling 36.63 11.18 95 50902 442750 110095552
Hypervolaemia 34.76 11.18 73 50924 49387 110488915
Fluid retention 33.77 11.18 108 50889 94199 110444103
Cardiac failure congestive 32.53 11.18 147 50850 150853 110387449
Ill-defined disorder 32.22 11.18 16 50981 156837 110381465
Mental status changes 31.78 11.18 92 50905 76030 110462272
Hospice care 30.41 11.18 33 50964 12440 110525862
Bursitis 30.29 11.18 11 50986 129907 110408395
Therapeutic product effect decreased 30.27 11.18 41 50956 244275 110294027
Hip fracture 29.65 11.18 56 50941 35095 110503207
Overdose 29.20 11.18 39 50958 233755 110304547
Flatulence 28.86 11.18 70 50927 52079 110486223
Influenza like illness 28.75 11.18 98 50899 88314 110449988
Dyspnoea exertional 27.63 11.18 108 50889 103952 110434350
Headache 27.61 11.18 565 50432 881812 109656490
Pollakiuria 27.38 11.18 62 50935 44133 110494169
Mobility decreased 27.29 11.18 42 50955 237380 110300922
Joint range of motion decreased 27.26 11.18 11 50986 121821 110416481
Back pain 27.19 11.18 276 50721 370720 110167582
Prescribed overdose 27.15 11.18 4 50993 87577 110450725
Haematocrit decreased 26.73 11.18 79 50918 66038 110472264
Blister 26.35 11.18 40 50957 227336 110310966
International normalised ratio increased 26.33 11.18 94 50903 86678 110451624
Hypercholesterolaemia 26.27 11.18 5 50992 90832 110447470
Asthma 26.24 11.18 47 50950 250244 110288058
White blood cell count decreased 25.96 11.18 188 50809 229202 110309100
Viral infection 25.93 11.18 68 50929 53071 110485231
Peripheral venous disease 25.71 11.18 4 50993 84113 110454189
Injection site pain 25.70 11.18 155 50842 177767 110360535
Urinary tract infection 25.49 11.18 246 50751 326036 110212266
Pelvic pain 25.43 11.18 34 50963 15908 110522394
Blood potassium decreased 25.14 11.18 68 50929 54046 110484256
Rheumatoid arthritis 24.97 11.18 64 50933 299549 110238753
Constipation 24.71 11.18 263 50734 357523 110180779
Cellulitis 24.44 11.18 119 50878 125897 110412405
Injection site erythema 24.41 11.18 97 50900 94079 110444223
Small intestinal obstruction 24.35 11.18 49 50948 32164 110506138
Pulmonary hypertension 24.27 11.18 68 50929 55152 110483150
Epilepsy 24.19 11.18 8 50989 100201 110438101
Obesity 24.14 11.18 11 50986 113340 110424962
Grip strength decreased 24.09 11.18 4 50993 80170 110458132
Pulmonary arterial hypertension 23.97 11.18 49 50948 32519 110505783
Pulmonary embolism 23.25 11.18 174 50823 214300 110324002
Monoparesis 22.78 11.18 18 50979 4535 110533767
Balance disorder 22.56 11.18 110 50887 116450 110421852
Hypertonic bladder 22.41 11.18 19 50978 5283 110533019
Injection site haemorrhage 22.34 11.18 48 50949 32980 110505322
Gastrointestinal disorder 22.29 11.18 49 50948 241903 110296399
Cytokine release syndrome 22.29 11.18 3 50994 70303 110467999
Tremor 21.89 11.18 164 50833 202068 110336234
Micturition urgency 21.81 11.18 35 50962 19285 110519017
Neuropathy peripheral 21.49 11.18 149 50848 179128 110359174
Pleural effusion 21.48 11.18 148 50849 177561 110360741
Nasal congestion 21.40 11.18 96 50901 98186 110440116
Platelet count decreased 21.18 11.18 180 50817 230263 110308039
Therapeutic response decreased 21.13 11.18 9 50988 96490 110441812
Oedema peripheral 21.04 11.18 238 50759 328422 110209880
Discomfort 21.03 11.18 42 50955 214665 110323637
Complication associated with device 20.81 11.18 35 50962 20038 110518264
Hypoxia 20.76 11.18 116 50881 129399 110408903
Impaired healing 20.56 11.18 37 50960 196680 110341622
Suicide attempt 20.56 11.18 11 50986 103383 110434919
Dysgeusia 20.54 11.18 75 50922 69910 110468392
Flushing 20.38 11.18 99 50898 104637 110433665
Chills 20.31 11.18 154 50843 190426 110347876
Wheezing 20.14 11.18 56 50941 255174 110283128
Gastrointestinal haemorrhage 20.09 11.18 138 50859 165380 110372922
Eye swelling 20.07 11.18 46 50951 33002 110505300
Exposure during pregnancy 19.83 11.18 29 50968 167395 110370907
Live birth 19.73 11.18 4 50993 69480 110468822
Product complaint 19.59 11.18 28 50969 13944 110524358
Cardiac disorder 19.31 11.18 78 50919 76202 110462100
Bronchitis 19.11 11.18 131 50866 156901 110381401
Illness 19.08 11.18 7 50990 82164 110456138
Drug ineffective for unapproved indication 18.95 11.18 12 50985 102826 110435476
Vaginal haemorrhage 18.78 11.18 38 50959 25036 110513266
Inflammation 18.75 11.18 38 50959 193200 110345102
Condition aggravated 18.70 11.18 233 50764 734603 109803699
Sleep disorder 18.49 11.18 40 50957 198604 110339698
Atrial fibrillation 18.35 11.18 174 50823 229468 110308834
Anxiety 18.23 11.18 241 50756 344837 110193465
Autoimmune disorder 18.12 11.18 4 50993 65479 110472823
Abdominal pain 17.86 11.18 334 50663 512655 110025647
Lung disorder 17.82 11.18 35 50962 180012 110358290
Weight decreased 17.44 11.18 308 50689 467749 110070553
Hypersensitivity 17.36 11.18 112 50885 403886 110134416
Transfusion 17.21 11.18 37 50960 25435 110512867
Drug-induced liver injury 17.16 11.18 18 50979 120049 110418253
Hepatic function abnormal 17.03 11.18 10 50987 89285 110449017
Bone pain 16.80 11.18 67 50930 65066 110473236
Nocturia 16.79 11.18 29 50968 16961 110521341
Wound infection 16.77 11.18 12 50985 96453 110441849
Chest pain 16.73 11.18 255 50742 376120 110162182
Laryngeal pain 16.69 11.18 17 50980 5958 110532344
Liver disorder 16.50 11.18 25 50972 142218 110396084
Hypertension 16.48 11.18 153 50844 509931 110028371
Red blood cell count decreased 16.36 11.18 67 50930 65856 110472446
Stomatitis 16.07 11.18 67 50930 270175 110268127
Atelectasis 15.93 11.18 45 50952 36667 110501635
Disease progression 15.74 11.18 177 50820 243857 110294445
Depression 15.68 11.18 219 50778 317116 110221186
Thrombosis 15.26 11.18 94 50903 108568 110429734
Infection 15.26 11.18 101 50896 362099 110176203
Ataxia 15.17 11.18 39 50958 30069 110508233
Pain in jaw 15.15 11.18 55 50942 51122 110487180
Eosinophilia 15.13 11.18 4 50993 57932 110480370
Myalgia 15.12 11.18 163 50834 222218 110316084
Hypophagia 15.11 11.18 56 50941 52570 110485732
Heavy menstrual bleeding 14.97 11.18 27 50970 16338 110521964
Erectile dysfunction 14.96 11.18 29 50968 18527 110519775
Agranulocytosis 14.79 11.18 5 50992 61755 110476547
Depressed level of consciousness 14.77 11.18 18 50979 112260 110426042
Gallbladder disorder 14.73 11.18 31 50966 20998 110517304
Central nervous system lesion 14.66 11.18 26 50971 15527 110522775
Multiple organ dysfunction syndrome 14.57 11.18 30 50967 151680 110386622
Infective pulmonary exacerbation of cystic fibrosis 14.32 11.18 25 50972 14746 110523556
Cholestasis 14.15 11.18 6 50991 64512 110473790
Application site erythema 13.95 11.18 15 50982 5595 110532707
Blepharospasm 13.92 11.18 4 50993 54847 110483455
Interstitial lung disease 13.86 11.18 27 50970 139307 110398995
Cytomegalovirus infection 13.76 11.18 4 50993 54440 110483862
Gait disturbance 13.74 11.18 192 50805 278016 110260286
Blood glucose decreased 13.64 11.18 37 50960 29451 110508851
Vision blurred 13.60 11.18 104 50893 128918 110409384
Blood cholesterol increased 13.52 11.18 42 50955 184743 110353559
Nail disorder 13.34 11.18 5 50992 57930 110480372
Drug reaction with eosinophilia and systemic symptoms 13.27 11.18 11 50986 82084 110456218
Rotator cuff syndrome 13.24 11.18 26 50971 16768 110521534
Sleep disorder due to a general medical condition 12.86 11.18 4 50993 52108 110486194
Transient ischaemic attack 12.82 11.18 61 50936 63921 110474381
Drug resistance 12.76 11.18 5 50992 56369 110481933
Pulmonary fibrosis 12.76 11.18 17 50980 102025 110436277
Aspartate aminotransferase increased 12.68 11.18 121 50876 159815 110378487
Psoriasis 12.67 11.18 109 50888 139884 110398418
Lethargy 12.55 11.18 80 50917 93496 110444806
Hot flush 12.54 11.18 62 50935 65974 110472328
Cardiac pacemaker insertion 12.53 11.18 15 50982 6286 110532016
Bone erosion 12.50 11.18 3 50994 46368 110491934
Influenza 12.46 11.18 126 50871 168975 110369327
Application site pain 12.46 11.18 14 50983 5485 110532817
Swelling face 12.43 11.18 79 50918 92242 110446060
Alopecia 12.39 11.18 108 50889 364645 110173657
Osteoarthritis 12.33 11.18 43 50954 182580 110355722
Application site discolouration 12.19 11.18 7 50990 1042 110537260
Hospitalisation 11.89 11.18 109 50888 142384 110395918
Abdominal adhesions 11.85 11.18 12 50985 4178 110534124
Muscle spasticity 11.84 11.18 40 50957 35875 110502427
Granulocytopenia 11.66 11.18 21 50976 12694 110525608
Dialysis 11.57 11.18 27 50970 19592 110518710
Rib fracture 11.48 11.18 38 50959 33732 110504570
Rash pruritic 11.45 11.18 81 50916 97988 110440314
Intestinal dilatation 11.41 11.18 11 50986 3609 110534693
Blood glucose increased 11.39 11.18 102 50895 132394 110405908

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
MeSH PA D000960 Hypolipidemic Agents
MeSH PA D000963 Antimetabolites
MeSH PA D005765 Gastrointestinal Agents
MeSH PA D008082 Lipotropic Agents
MeSH PA D018697 Nootropic Agents
MeSH PA D057847 Lipid Regulating Agents
CHEBI has role CHEBI:25512 neurotransmitter
CHEBI has role CHEBI:33284 nutrient
CHEBI has role CHEBI:50904 allergen
CHEBI has role CHEBI:75771 mouse metabolite
CHEBI has role CHEBI:75772 <em>Saccharomyces cerevisiae </em> metabolite
CHEBI has role CHEBI:76924 plant metabolite
CHEBI has role CHEBI:76971 <em>Escherichia coli</em> metabolite
CHEBI has role CHEBI:77746 human metabolite
CHEBI has role CHEBI:83056 <em>Daphnia magna</em> metabolite
CHEBI has role CHEBI:82655 animal growth promotant

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Insomnia indication 193462001




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Acetylcholine receptor subunit delta Ion channel Ki 4.38 CHEMBL
High affinity choline transporter 1 Transporter IC50 5.80 CHEMBL
Neuronal acetylcholine receptor; alpha2/beta2 Ion channel Ki 4.74 CHEMBL
Neuronal acetylcholine receptor; alpha3/beta2 Ion channel Ki 4.43 CHEMBL
Neuronal acetylcholine receptor; alpha3/beta4 Ion channel Ki 4.32 CHEMBL
Neuronal acetylcholine receptor; alpha4/beta2 Ion channel Ki 4.43 CHEMBL
Neuronal acetylcholine receptor; alpha4/beta4 Ion channel Ki 4.47 CHEMBL
Creatine transporter Transporter Ki 4.38 CHEMBL

External reference:

IDSource
N91BDP6H0X UNII
4020078 VUID
N0000178902 NUI
D07690 KEGG_DRUG
67-48-1 SECONDARY_CAS_RN
4017687 VANDF
4017699 VANDF
4020077 VANDF
4020078 VANDF
C0008405 UMLSCUI
CHEBI:15354 CHEBI
CHT PDB_CHEM_ID
CHEMBL920 ChEMBL_ID
305 PUBCHEM_CID
DB00122 DRUGBANK_ID
CHEMBL282468 ChEMBL_ID
CHEMBL2105935 ChEMBL_ID
D002794 MESH_DESCRIPTOR_UI
4551 IUPHAR_LIGAND_ID
87-67-2 SECONDARY_CAS_RN
1425426 RXNORM
43412 MMSL
4436 MMSL
4437 MMSL
4875 MMSL
4880 MMSL
NOCODE MMSL
d03064 MMSL
d03159 MMSL
002058 NDDF
002059 NDDF
005105 NDDF
111156002 SNOMEDCT_US
387030006 SNOMEDCT_US
427976002 SNOMEDCT_US
65123005 SNOMEDCT_US
442 INN_ID
N91BDP6H0X INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
NESTABSPrenatal Multi-vitamin/Mineral Supplement HUMAN PRESCRIPTION DRUG LABEL 15 50967-219 TABLET, FILM COATED 55 mg ORAL unapproved drug other 8 sections
Prenatol-M HUMAN PRESCRIPTION DRUG LABEL 20 59088-009 TABLET 55 mg ORAL unapproved drug other 13 sections
Vitalux HUMAN PRESCRIPTION DRUG LABEL 20 59088-139 TABLET 55 mg ORAL unapproved drug other 13 sections
Prenatrix HUMAN PRESCRIPTION DRUG LABEL 20 59088-166 TABLET 55 mg ORAL unapproved drug other 13 sections
Prenatryl HUMAN PRESCRIPTION DRUG LABEL 20 59088-169 TABLET 55 mg ORAL unapproved drug other 13 sections
Prometa HUMAN PRESCRIPTION DRUG LABEL 20 59088-172 TABLET 55 mg ORAL unapproved drug other 13 sections
Pretrate HUMAN PRESCRIPTION DRUG LABEL 20 59088-178 TABLET 55 mg ORAL unapproved drug other 13 sections
Livita Adults HUMAN PRESCRIPTION DRUG LABEL 17 59088-659 LIQUID 200 mg ORAL unapproved drug other 10 sections
Livita Children HUMAN PRESCRIPTION DRUG LABEL 17 59088-660 LIQUID 66.67 mg ORAL unapproved drug other 10 sections
Lipovite HUMAN PRESCRIPTION DRUG LABEL 13 70104-128 INJECTION 1 mg INTRAMUSCULAR unapproved drug other 1 sections